Search results for "MUTATION"

showing 10 items of 2830 documents

Small and dense LDL in Familial Combined Hyperlipidemia and N291S polymorphism of the lipoprotein lipase gene

2009

18 pagesm 2 figures. -- PMID: 19335919 [PubMed]

AdultMalemedicine.medical_specialtyApolipoprotein BAdolescentEndocrinology Diabetes and MetabolismPopulationClinical BiochemistryHyperlipidemia Familial CombinedMutation MissenseBlood lipidschemistry.chemical_compoundYoung AdultHigh-density lipoproteinEndocrinologyInternal medicinePrevalenceMedicineShort PaperHumanseducationlcsh:RC620-627AgedBiochemistry medicalLipoprotein lipaseeducation.field_of_studyPolymorphism Geneticmedicine.diagnostic_testbiologyCholesterolbusiness.industryBiochemistry (medical)Cholesterol LDLMiddle AgedAtherosclerosisLipidslcsh:Nutritional diseases. Deficiency diseasesLipoprotein LipaseEndocrinologychemistrySpainLow-density lipoproteinCase-Control Studiesbiology.proteinFemalelipids (amino acids peptides and proteins)businessLipid profile
researchProduct

Analysis of the gastrin-releasing peptide receptor gene in Italian patients with autism spectrum disorders

2008

The gastrin-releasing peptide receptor (GRPR) was implicated for the first time in the pathogenesis of Autism spectrum disorders (ASD) by Ishikawa-Brush et al. [Ishikawa-Brush et al. (1997): Hum Mol Genet 6: 1241-1250]. Since this original observation, only one association study [Marui et al. (2004): Brain Dev 26: 5-7] has further investigated, though unsuccessfully, the involvement of the GRPR gene in ASD. With the aim of contributing further information to this topic we have sequenced the entire coding region and the intron/exon junctions of the GRPR gene in 149 Italian autistic patients. The results of this study led to the identification of four novel point mutations, two of which, that…

AdultMalemedicine.medical_specialtyBALB 3T3 CellsAdolescentDNA Mutational AnalysisPopulationRett syndromeBiologyMiceCellular and Molecular NeuroscienceExonSettore BIO/13 - Biologia ApplicataInternal medicineGastrin-releasing peptideChlorocebus aethiopsmedicineGastrin-releasing peptide receptorAnimalsHumansPoint MutationAutistic DisorderChildautism gastrin-releasing peptide receptor signal transductionG-protein-coupled receptor association studyeducationGeneGenetics (clinical)AgedGeneticseducation.field_of_studyPoint mutationMiddle Agedmedicine.diseasePedigreeReceptors BombesinDevelopmental disorderPsychiatry and Mental healthEndocrinologyItalyCase-Control StudiesCOS CellsFemaleAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics
researchProduct

Franceschetti Hereditary Recurrent Corneal Erosion

2011

To describe new affected individuals of Franceschetti's original pedigree of hereditary recurrent erosion and to classify a unique entity called Franceschetti corneal dystrophy.Observational case series.Slit-lamp examination of 10 affected individuals was conducted. Biomicroscopic examinations were supplemented by peripheral corneal biopsy in 1 affected patient with corneal haze. Tissue was processed for light and electron microscopy and immunohistochemistry was performed. DNA analysis was carried out in 12 affected and 3 nonaffected family members.All affected individuals suffered from severe ocular pain in the first decade of life, attributable to recurrent corneal erosions. Six adult pat…

AdultMalemedicine.medical_specialtyBiopsyDNA Mutational AnalysisDermatan SulfateCorneal dystrophyCorneal OpacityCorneal erosionAntigens NeoplasmRecurrenceTransforming Growth Factor betaOphthalmologymedicineEye PainHumansChildAgedAged 80 and overCorneal Dystrophies HereditaryExtracellular Matrix Proteinsbusiness.industryCadherinsmedicine.diseaseImmunohistochemistryPedigreeRecurrent corneal erosionOphthalmologyClaudinsFemaleDecorinbusinessCell Adhesion MoleculesChondroitinBiomarkersAmerican Journal of Ophthalmology
researchProduct

Non-classic cystic fibrosis associated with D1152HCFTR mutation

2010

Burgel P-R, Fajac I, Hubert D, Grenet D, Stremler N, Roussey M, Siret D, Languepin J, Mely L, Fanton A, Labbe A, Domblides P, Vic P, Dagorne M, Reynaud-Gaubert M, Counil F, Varaigne F, Bienvenu T, Bellis G, Dusser D. Non-classic cystic fibrosis associated with D1152H CFTR mutation. Background: Limited knowledge exists on phenotypes associated with the D1152H cystic fibrosis transmembrane conductance regulator (CFTR) mutation. Methods: Subjects with a D1152H allele in trans with another CFTR mutation were identified using the French Cystic Fibrosis Registry. Phenotypic characteristics were compared with those of pancreatic insufficient (PI) and pancreatic sufficient (PS) cystic fibrosis (CF)…

AdultMalemedicine.medical_specialtyConsensusPancreatic diseaseAdolescentCystic FibrosisGENETICSmedicine.medical_treatmentCystic Fibrosis Transmembrane Conductance RegulatorCystic fibrosisGastroenterologyMembrane PotentialsCohort StudiesYoung AdultChloridesInterquartile rangeForced Expiratory VolumeInternal medicineCYSTIC_FIBROSISHumansMedicineLung transplantationGenetic Predisposition to DiseaseChildSweatExocrine pancreatic insufficiencyMUTATIONGenetics (clinical)AgedBronchiectasisbiologybusiness.industryHomozygoteMiddle Agedmedicine.diseaseCongenital absence of the vas deferensCystic fibrosis transmembrane conductance regulatorNasal MucosaEndocrinologyAmino Acid SubstitutionChild Preschoolbiology.proteinFemalebusiness
researchProduct

Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5.

2020

Arrhythmogenic right ventricular cardiomyopathy type V (ARVC-5) is the most aggressive heterozygous form of ARVC. It is predominantly caused by a fully penetrant mutation (p.S358L) in the nondesmosomal gene TMEM43-endemic to Newfoundland, Canada. To date, all familial cases reported worldwide share a common ancestral haplotype. It is unknown whether the p.S358L mutation by itself causes ARVC-5 or whether the disease is influenced by genetic or environmental factors. The purpose of this study was to examine the phenotype, clinical course, and the impact of exercise on patients with p.S358L ARVC-5 without the Newfoundland genetic background. We studied 62 affected individuals and 73 noncarrie…

AdultMalemedicine.medical_specialtyDNA Mutational AnalysisMutation MissenseDisease030204 cardiovascular system & hematologyVentricular Function LeftRight ventricular cardiomyopathySudden cardiac deathElectrocardiography03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicinemedicineGeneticsHumans030212 general & internal medicineExerciseArrhythmogenic Right Ventricular DysplasiaEjection fractionTMEM43business.industryIncidence (epidemiology)HaplotypeMembrane ProteinsStroke VolumeDNAmedicine.diseasePhenotypePedigree3. Good healthPhenotypeMutation (genetic algorithm)CardiologyFemaleCardiology and Cardiovascular MedicinebusinessArrhythmogenic right ventricular cardiomyopathyArrhythmia
researchProduct

Hereditary angioedema with normal C1-INH withversuswithout specificF12gene mutations

2015

Background Hereditary angioedema with normal C1-INH may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or mutations in genes that are still unknown (HAE-unknown). To assess the differences in transmission and inheritance, clinical features, and laboratory parameters between patients with HAE-FXII and HAE-unknown. Methods Sixty-nine patients with HAE-FXII from 23 unrelated families and 196 patients with HAE-unknown from 65 unrelated families were studied. Results Both HAE-FXII and HAE-unknown are inherited as autosomal-dominant traits with incomplete penetrance. The male to female ratio was 1 : 68 in HAE-FXII and 1 : 6.3 in HAE-unknown. The maternal to pa…

AdultMalemedicine.medical_specialtyDatabases FactualOffspringImmunologyGene mutationSeverity of Illness IndexCohort StudiesYoung Adultchemistry.chemical_compoundAge DistributionInternal medicineHumansImmunology and AllergyMedicineHereditary Angioedema Type IIIAge of OnsetSex DistributionRetrospective Studiesmedicine.diagnostic_testAngioedemabusiness.industryIncidenceAngioedemas HereditaryMiddle AgedPrognosismedicine.diseasePenetranceRecombinant ProteinsPedigreePhenotypeEndocrinologychemistryPlasminogen activator inhibitor-1Factor XIIMutationHereditary angioedemaFemalemedicine.symptombusinessComplement C1 Inhibitor ProteinPartial thromboplastin timeAllergy
researchProduct

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

2011

The NOA-05 multicenter trial was performed to analyze the efficacy of primary chemotherapy with procarbazine and lomustine (PC) in patients with gliomatosis cerebri (GC) and to define clinical, imaging, and molecular factors influencing outcome.Thirty-five patients with previously untreated GC were treated with up to six 56-day courses of 110mg/m(2) lomustine on day 1 and 60mg/m(2) procarbazine on days 8 to 21. The primary endpoint was the rate of patients without therapy failure (defined as progressive disease, death from any cause, or termination of PC therapy before the end of course 4) at 8 months after the beginning of PC chemotherapy.The failure-free survival rate at 8 months was 50.3…

AdultMalemedicine.medical_specialtyEndpoint DeterminationGliomatosis cerebriAntineoplastic AgentsGene mutationProcarbazineGastroenterologyDisease-Free SurvivalLomustineInternal medicineMulticenter trialAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumorMedicineHumansProspective StudiesKarnofsky Performance StatusSurvival rateDNA Modification MethylasesAgedbusiness.industryTumor Suppressor ProteinsHazard ratioBrainLomustineMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyMagnetic Resonance ImagingNeoplasms NeuroepithelialSurvival AnalysisSurgeryDNA Repair EnzymesTreatment OutcomeNeurologyProcarbazineSample SizeDisease ProgressionFemaleNeurology (clinical)businessProgressive diseasemedicine.drugAnnals of neurology
researchProduct

Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.

2009

Abstract Background/aim To present clinical and genetic characteristics of all Romanian patients with Gaucher disease type 1, in whom specific diagnosis has been confirmed by enzymatic and molecular methods and to analyze their outcome with and without enzymatic replacement therapy (ERT). Patients, methods There are fifty patients (F/M — 1.63/1) with Gaucher disease type 1. Clinical status, haemoglobin, thrombocytes, hepatic/splenic volume, bone mineral density and severity score were assessed at baseline and every six months thereafter. Thirty-nine patients (78%) received imiglucerase (44.4 ± 13.6 U/kg/2 weeks) for 3.1 +/− 1.4 years. Results Based on general prevalence data, our group repr…

AdultMalemedicine.medical_specialtyEvery Six MonthsBone diseaseImigluceraseAdolescentGenotypeDiseaseGastroenterologyYoung AdultInternal medicineGenotypeInternal MedicinemedicineHumansPlateletAge of OnsetChildAllelesBone mineralGaucher Diseasebusiness.industryRomaniaInfantAnemiaMiddle Agedmedicine.diseasePrognosisThrombocytopeniaSurgeryHexosaminidasesChild PreschoolMutationSplenomegalyGlucosylceramidaseFemalebusinessVisceromegalymedicine.drugEuropean journal of internal medicine
researchProduct

Norepinephrine transporter gene polymorphism is not associated with susceptibility to alcohol dependence

2002

Abnormalities in monoamine neurotransmission have been implicated in the pathogenesis of alcoholism, mood disorders and schizophrenia. Murine norepinephrine transporter gene (NET) has been mapped to a region on chromosome 8 where a quantitative trait locus for ethanol sensitivity. Therefore we tested whether norepinephrine transporter (NET) gene variants confer susceptibility to either alcohol dependence or severe alcohol withdrawal symptoms. There is a highly polymorphic silent G1287A mutation in the NET gene. In our study 157 alcoholics and 185 healthy unrelated matched control subjects were analyzed for a silent G1287A mutation. No significant differences in allele and genotype distribut…

AdultMalemedicine.medical_specialtyGenotypeDNA Mutational AnalysisMolecular Sequence DataAlcohol Withdrawal DeliriumGene FrequencyPolymorphism (computer science)Internal medicineGenotypemedicineHumansGenetic Predisposition to DiseaseRNA MessengerAlleleAllelesBiological PsychiatryGeneticsNorepinephrine Plasma Membrane Transport ProteinsPolymorphism GeneticSymportersbiologybusiness.industryAlcohol dependenceExonsMiddle Agedmedicine.diseaseAlcoholismPsychiatry and Mental healthMonoamine neurotransmitterEndocrinologyMood disordersNorepinephrine transporterbiology.proteinFemaleGene polymorphismbusinessPolymorphism Restriction Fragment LengthPsychiatry Research
researchProduct

Association between M467T and 114 C--A variants within the SLC3A1 gene and some phenotypical traits in cystinuria patients from Spain.

2000

Cystinuria is an inherited metabolic disease characterized by an abnormal urinary excretion of cystine and dibasic amino acids. Formation of renal calculi, recurrent infections and renal failure are the main complications of this disease. The SLC3A1 gene, which codes for a dibasic amino acid transporter protein, is involved in the pathogenesis of cystinuria. We investigated the possible association between molecular variants (M467T, E483X, T216 M and 114 C--A) within the SLC3A1 gene and some phenotypical traits in a Spanish area. The study population consisted of 45 cystinuria patients, 42 cystinuria relatives and 81 healthy control subjects. Only the M467T mutation was found in chromosomes…

AdultMalemedicine.medical_specialtyGenotypeUrinary systemCystineBiologychemistry.chemical_compoundKidney CalculiSex FactorsMale Urogenital DiseasesInternal medicineGenotypeGeneticsmedicineHumansAlleleAmino AcidsChildAllele frequencyGenetics (clinical)AllelesCystinuriaMembrane GlycoproteinsPolymorphism GeneticMediterranean RegionAge FactorsCystinuriamedicine.diseaseFemale Urogenital DiseasesEndocrinologyPhenotypechemistrySpainAminoaciduriaMutationPopulation studyAmino Acid Transport Systems BasicRegression AnalysisFemaleCarrier ProteinsHuman genetics
researchProduct